Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study

Journal of Clinical Oncology

Volumn 35, Issue 7, 2017, Pages 751-758

  Visvanathan, Kala ^a   Fackler, Maryjo S ^a   Zhang, Zhe ^a   Lopez Bujanda, Zoila A ^a   Jeter, Stacie C ^a   Sokoll, Lori J ^a   Garrett Mayer, Elizabeth ^b   Cope, Leslie M ^a   Umbricht, Christopher B ^a   Euhus, David M ^a   Forero, Andres ^c   Storniolo, Anna M ^d   Nanda, Rita ^e   Lin, Nancy U ^f   Carey, Lisa A ^g   Ingle, James N ^h   Sukumar, Saraswati ^a   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; DNA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DNA METHYLATION; EPIGENETICS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MONITORING; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUANTITATIVE ASSAY; RISK ASSESSMENT; TRIPLE NEGATIVE BREAST CANCER; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85013999091     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.2080     Document Type: Article

References (30)

1. Tie J, Kinde I, Wang Y, et al: Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26:1715-1722, 2015
2. Smerage JB, Hayes DF: The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer 94:8-12, 2006
3. Van Poznak C, Somerfield MR, Bast RC, et al: Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 33:2695-2704, 2015
4. Egger G, Liang G, Aparicio A, et al: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463, 2004
5. Baylin S: DNA methylation and epigenetic mechanisms of carcinogenesis. Dev Biol (Basel) 106:85-87, discussion 143-160, 2001
6. Jones PA: DNA methylation and cancer. Oncogene 21:5358-5360, 2002
7. Fackler MJ, Lopez Bujanda Z, Umbricht C, et al: Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-2170, 2014
8. Evron E, Dooley WC, Umbricht CB, et al: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357:1335-1336, 2001
9. Fackler MJ, Malone K, Zhang Z, et al: Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12:3306-3310, 2006
10. Fackler MJ, McVeigh M, Mehrotra J, et al: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64:4442-4452, 2004
11. Fackler MJ, Rivers A, Teo WW, et al: Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin Cancer Res 15:3802-3811, 2009
12. Fiegl H, Millinger S, Mueller-Holzner E, et al: Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65:1141-1145, 2005
13. Chimonidou M, Tzitzira A, Strati A, et al: CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin Biochem 46:235-240, 2013
14. Fujita N, Kagara N, Yamamoto N, et al: Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis. Oncol Lett 8:397-403, 2014
15. Göbel G, Auer D, Gaugg I, et al: Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat 130:109-117, 2011
16. Fackler MJ, Umbricht CB, Williams D, et al: Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71:6195-6207, 2011
17. Contal C, O'Quigley J: An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30:253-270, 1999
18. Faraggi D, Simon R: A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med 15:2203-2213, 1996
19. Tworoger SS, Hankinson SE: Use of biomarkers in epidemiologic studies: Minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 17:889-899, 2006
20. Freedman TS, Sondermann H, Friedland GD, et al: A Ras-induced conformational switch in the Ras activator Son of sevenless. Proc Natl Acad Sci USA 103:16692-16697, 2006
21. Gordon M, Baksh S: RASSF1A: Not a prototypical Ras effector. Small GTPases 2:148-157, 2011
22. MacAlpine DM, Almouzni G: Chromatin and DNA replication. Cold Spring Harb Perspect Biol 5:a010207, 2013
23. Watanabe K: Recent reports about enzymes related to the synthesis of prostaglandin (PG) F (2) (PGF(2α) and 9α, 11β-PGF(2)). J Biochem 150:593-596, 2011
24. Lin SH, Wang J, Saintigny P, et al: Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 15:1079, 2014
25. Avraham A, Uhlmann R, Shperber A, et al: Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 131:E1166-E1172, 2012
26. Van der Auwera I, Elst HJ, Van Laere SJ, et al: The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 100:1277-1286, 2009
27. Ahmed SA, Hamed MA, Omar OS: Clinical utility of certain biomarkers as predictors of breast cancer with or without metastasis among Egyptian females. Tumour Biol 36:815-822, 2015
28. Dawson SJ, Rosenfeld N, Caldas C: Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 369:93-94, 2013
29. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004
30. Smerage JB, Barlow WE, Hortobagyi GN, et al: Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-3489, 2014